Aarkstore - Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy
The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. Browse full report @ http://goo.gl/INmidr
The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands.
Browse full report @ http://goo.gl/INmidr
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
<strong>Biopharma</strong> M&A <strong>and</strong> <strong>Deal</strong> <strong>Making</strong> - Underst<strong>and</strong>ing <strong>the</strong> <strong>Latest</strong><br />
<strong>Trends</strong> <strong>to</strong> <strong>Optimize</strong> <strong>Future</strong> <strong>Strategy</strong><br />
Browse Full Report @<br />
http://www.aarks<strong>to</strong>re.com/healthcare/109260/biopharma-ma-<strong>and</strong>deal-making-underst<strong>and</strong>ing-<strong>the</strong>-latest-trends-<strong>to</strong>-optimize-futurestrategy<br />
Summary<br />
Published: Mar. 2013| No. Of Pages: 55 Pages<br />
The leading pharmaceutical players continue <strong>to</strong> face <strong>the</strong> combined threats of a difficult operating environment<br />
<strong>and</strong> patent losses while struggling <strong>to</strong> deliver on pipeline potential. Externalization strategies are a key means<br />
<strong>to</strong> boost future revenues <strong>and</strong>, indeed more imminently, <strong>to</strong> satisfy shareholder dem<strong>and</strong>s. However, <strong>the</strong><br />
increasing size of <strong>the</strong> leading biopharmaceutical companies is necessitating <strong>the</strong>ir involvement in growing <strong>the</strong><br />
numbers <strong>and</strong> size of deals year by year. This in itself, along with <strong>the</strong> rising financial firepower of <strong>the</strong> mid-tier<br />
players, has increased <strong>the</strong> level of competition for <strong>the</strong> most attractive targets.<br />
Increased competition in <strong>the</strong> marketplace for M&A <strong>and</strong> licensing deals can artificially inflate <strong>the</strong> cost of <strong>the</strong>se<br />
deals, dis<strong>to</strong>rting <strong>the</strong> balance of value, risk <strong>and</strong> return. As a result companies must employ more rigorous<br />
selection processes <strong>and</strong> exp<strong>and</strong> search criteria <strong>to</strong> consider more diverse options if <strong>the</strong>y are <strong>to</strong> maximize <strong>the</strong>ir<br />
returns on investment.<br />
The report, “<strong>Biopharma</strong> M&A <strong>and</strong> <strong>Deal</strong> <strong>Making</strong> - Underst<strong>and</strong>ing <strong>the</strong> <strong>Latest</strong> <strong>Trends</strong> <strong>to</strong> <strong>Optimize</strong> <strong>Future</strong><br />
<strong>Strategy</strong>”, was written <strong>to</strong> support team <strong>and</strong> corporate strategic initiatives around <strong>the</strong> options that exist <strong>to</strong><br />
grow revenues through externalization, whe<strong>the</strong>r by M&A or licensing. CBR Pharma Insights provides in-depth<br />
analysis on <strong>the</strong> deals being done <strong>to</strong>day, <strong>the</strong> trends being seen over time, <strong>and</strong> <strong>the</strong> strategies employed<br />
throughout <strong>the</strong> industry.<br />
Scope<br />
- <strong>Trends</strong> in recent deal activity<br />
- Successful deal making<br />
- <strong>Future</strong> deal activity
<strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
Key Reasons <strong>to</strong> Purchase<br />
- Underst<strong>and</strong> <strong>and</strong> evaluate <strong>the</strong> strategies being used by companies of all sizes <strong>to</strong> support future revenue<br />
growth<br />
- Benefit from CBR’s case study analysis of <strong>the</strong> different types of deals being done in <strong>the</strong> current & future<br />
biopharma industry<br />
- Access data <strong>and</strong> trends analysis of <strong>the</strong> types of deals taking place <strong>and</strong> which <strong>the</strong>rapeutic areas are showing<br />
<strong>the</strong> most activity<br />
- Gain insights around <strong>the</strong> steps that need <strong>to</strong> be taken in order <strong>to</strong> best secure a successful deal<br />
- Learn who <strong>the</strong> key companies are <strong>to</strong> watch for in <strong>the</strong> coming year, <strong>the</strong> motivations behind <strong>the</strong> deals <strong>the</strong>y are<br />
doing, <strong>and</strong> identify which ones relate <strong>to</strong> your business strategies<br />
You can order full Report with TOC <strong>and</strong> for Sample page visit @<br />
http://www.aarks<strong>to</strong>re.com/healthcare/109260/biopharma-ma-<strong>and</strong>-deal-making-underst<strong>and</strong>ing<strong>the</strong>-latest-trends-<strong>to</strong>-optimize-future-strategy<br />
Table Of Content<br />
Executive Summary<br />
Chapter 1: Introduction<br />
What is driving <strong>the</strong> increased use of externalization in biopharma industry strategies<br />
Externalization strategies: <strong>the</strong> options<br />
Benefits of different deal types from M&A <strong>to</strong> arms length licensing<br />
Chapter 2: <strong>Trends</strong> in recent deal activity<br />
M&A deal trends<br />
Key acquisitions in 2012 <strong>and</strong> <strong>the</strong> motives behind <strong>the</strong>m<br />
Most acquisitive companies<br />
Licensing deal trends (Type of deal, Therapy area, Phase)<br />
Divesting - <strong>the</strong> o<strong>the</strong>r extreme<br />
Focus on: <strong>Deal</strong> activity in <strong>the</strong> generics sec<strong>to</strong>r<br />
Chapter 3: Successful deal making<br />
Key steps <strong>to</strong> successful deal making<br />
Shift <strong>to</strong> earlier stage deals<br />
Differentiating capabilities <strong>to</strong> position company as "partner of choice“<br />
Focus on: Joint ventures in emerging markets<br />
Chapter 4: <strong>Future</strong> deal activity<br />
Key companies <strong>to</strong> watch in 2013
<strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
Related reports:<br />
Healthcare IT (HIT) Market in <strong>the</strong> APAC Region 2015-2019<br />
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report<br />
<strong>Latest</strong> Regulations on Pharmaceutical International Multi-Center Clinical Trials in China<br />
Colposcopy Test, Market, Users & Forecast - Asia & Middle East Analysis<br />
Asia Intrauterine Device (IUD) Market, Users & Forecast<br />
Global HER-2 Positive Breast Cancer Market 2015-2019<br />
European Non-Invasive & Minimally Invasive Cardiac Output Moni<strong>to</strong>ring Devices Market<br />
Point of Care Diagnostic Testing World Markets<br />
Kidney Transplant Market, Numbers & Forecast for United States, Mexico & Canada<br />
North American Labora<strong>to</strong>ry Information System (LIS) Market<br />
About <strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
<strong>Aarks<strong>to</strong>re</strong> Enterprise is a leading provider of business <strong>and</strong> financial information <strong>and</strong> solutions worldwide. We<br />
specialize in providing online market business information on market research reports, books, magazines,<br />
conference at competitive prices, <strong>and</strong> strive <strong>to</strong> provide excellent <strong>and</strong> innovative service <strong>to</strong> our cus<strong>to</strong>mers.<br />
Contact Details:<br />
<strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
Phone: +91 998 729 5242 / +91 - 22 2756 4953<br />
Email: enquiry@aarks<strong>to</strong>re.com<br />
Our Website: http://www.aarks<strong>to</strong>re.com<br />
Our Blog : http://www.aarks<strong>to</strong>re.com/blog/<br />
Our News Section : http://www.aarks<strong>to</strong>re.com/news
Change language